NSCLC

  •   George Lundberg, MD

    As reported by The ASCO Post, the drug adagrasib has shown some promising results in a clinical trial for people with advanced non-small cell lung cancer (NSCLC) with a KRAS-g12c mutation whose cancer progressed after prior treatment. The U.S. Food and Drug Administration (FDA) allows adagrasib to be given to people whose cancer has a KRAS-g12c mutation through expanded access.

    .

  •  

    New Targeted Treatment Options for Non-Small Cell Lung Cancer in 2021

    Emma Shtivelman, PhD

    Chemotherapy was once the only treatment available for metastatic or advanced non-small lung cancer (NSCLC). But the situation has changed dramatically in recent years. NSCLC may harbor mutations that drive cancer development, and many of these mutations can be targeted with precision drugs that inhibit specific mutant proteins. Targeted drugs not only often prolong survival of patients compared to chemotherapy, but they also improve… Read more »

  •   George Lundberg, MD

    On May 28, 2021, the U.S. Food and Drug Administration granted Accelerated Approval for Lumakras (sotorasib), the first targeted therapy for cancer with a mutation in the KRAS gene.

    .

  •  

    How an Expert Would Treat His Own Advanced Lung Cancer

    With: Jack West, MD

    A new cancer diagnosis is overwhelming. Patients often ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks lung cancer expert Howard (Jack) West, MD, how he would handle his own diagnosis of advanced lung cancer. Dr. West is a Princeton- and Harvard-educated oncologist with additional training and experience in Boston and Seattle focusing on lung cancer.… Read more »

  •   George Lundberg, MD

    This article from MedPage Today discusses recent study findings demonstrating that patients with complex cases of non-small cell lung cancer can benefit from the insights of a molecular tumor board.

    .

  •   George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved a liquid biopsy test (a type of biopsy that uses a blood draw instead of surgery) for detecting whether patients have EGFR mutations in their metastatic lung tumors, which could help guide treatment options.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research highlight from Nature Reviews Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    This year’s virtual meeting of the American Society of Clinical Oncology featured presentations on several different targeted therapies that appear to provide improved outcomes for lung cancer patients.

    Go to full research highlight published by Nature Reviews Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    The drug osimertinib (brand name Tagrisso) is beneficial as an adjuvant therapy—treatment given in addition to tumor-removal surgery—for patients with stage IB–IIIA non-small cell lung cancer (NSCLC) that has a mutation in the EGFR gene.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from OncLive curated by Editor in Chief George Lundberg, MD, who notes:

    The U.S. Food and Drug Administration (FDA) has approved another new drug for people with metastatic non-small cell lung cancer (NSCLC) tumors that have high levels of a protein called PD-L1.

    Go to full article published by OncLive.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •  

    What’s New in Immunotherapy for Non-Small Cell Lung Cancer?

    Emma Shtivelman, PhD

    Chemotherapy was once the only treatment option for metastatic non-small cell lung cancer (NSCLC). But five years ago, immunotherapy—treatment that boosts a patient’s own immune system to fight cancer—came on the scene. In 2015, the U.S. Food and Drug Administration (FDA) approved the drug nivolumab (brand name Opdivo) as next-line treatment for NSCLC after chemotherapy. Today, new immunotherapy options continue to alter the NSCLC… Read more »